Management Team


Greg Brown
Interim Chief Executive Officer – BAppSc, MBA

35 years experience – medical devices and in-vitro-diagnostics. International roles for Baxter Diagnostics (Australia & UK), Senior Global Marketing Manager for Roche Molecular Systems, and VP Global Strategic Marketing for Digene Corp. Managing Director and CEO for ImpediMed Limited. Boards: StraxCorp, Minomic, UniQuest.


Roy Davis
Chief Medical Officer – MD, PhD, MHA

Roy Davis

30 years experience: clinical medicine (Neonatal, Pediatric Critical Care) and hospital administration. Clinical Assistant Professor, Department of Pediatrics, University of Washington. Consultant in health care standards and quality of care delivered.  CMO at Providence Alaska assisted in the implementation of MEWS and sepsis surveillance algorithms using the Microsoft Amalga platform across Providence Health & Services. Won a national Microsoft Healthcare innovation award for work with MEWS in 2012.

Richard Brandon
Chief Scientific Officer – BVSc (Hons), PhD, MBA

35 years experience as veterinary immunologist, molecular biologist, pathologist, animal and human healthcare R&D executive: Cornell, Sloan Kettering Cancer Research, University of Queensland, various private pathology laboratories, Genetrax, Plasvacc, BioNiche. Lead author on all Immunexpress patents; architect of IP strategy.


Leo McHugh
Director, Medical Science Liaison – BSc (Genetics), BSc (Comp Sci), PhD

15 years experience – statistics, epidemiological statistics, biostatistics, machine learning, management, re: complex biological information. VP – R&D and Director Bioinformatics (Immunexpress); Senior Computational Biologist, (Queensland Facility for Advanced Bioinformatics); Westmead Hospital (Sydney); NICTA (Australia’s ICT Research Centre of Excellence).

Greg Uhl
Director, Finance - BS (Accounting), MPAcc (Audit and Assurance)

15 years experience – corporate finance, accounting and assurance.  Oversight over GAAP reporting, development of technical accounting policies and ICFR.  Financial Controller (Immunexpress); Controller (GroupAero), Audit Manager (PricewaterhouseCoopers, RSM). Masters of Professional Accounting – University of Washington.


Thomas Yager
Director, Research & Development – BA, MS, PhD

30 years experience. University of Oregon, Weizmann Institute, Kings College London, Hospital for Sick Children (Toronto), and cross-appointment to Dept. Molecular/Medical Genetics, University of Toronto. Broad industry experience in biomarker discovery, development & validation of molecular diagnostic assays; multiple regulatory submissions in USA, Canada and Europe.

Kyle Serikawa
Director, Commercialization Programs – BA (Biol.), PhD


20 years experience. Postdoc (University of Washington) in genomic technologies focused on RNA and DNA analysis using high-throughput tools – oncology, infectious diseases, and immune disorders. Previous experience in Merck and Novo Nordisk A/S.